dRTA (distal renal tubular acidosis) results from the failure of the ␣-intercalated cells in the distal tubule of the nephron to acidify the urine. A truncated form of AE1 (anion-exchanger 1; Band 3), kAE1 (kidney isoform of AE1), is located in the basolateral membrane of the intercalated cell. Mutations in the AE1 gene cause autosomal dominant and recessive forms of dRTA. All the dominant dRTA mutations investigated cause aberrant trafficking of kAE1, resulting in its intracellular retention or mistargeting to the apical plasma membrane. Therefore the intracellular retention of hetero-oligomers containing wild-type and dRTA mutants, or the mistargeted protein in the apical membrane neutralizing acid secretion, explains dominant dRTA. The kAE1 (Arg 901 →stop) mutant has been studied in more detail, since the mistargeting kAE1 (Arg 901 →stop) from the basolateral to the apical membrane is consistent with the removal of a basolateral localization signal. The C-terminal amino acids deleted by the Arg 901 →stop mutation, contain a tyrosine motif and a type II PDZ interaction domain. The tyrosine residue (Tyr 904 ), but not the PDZ domain, is critical for basolateral localization. In the absence of the N-terminus of kAE1, the C-terminus was not sufficient to localize kAE1 to the basolateral membrane. This suggests that a determinant within the kAE1 N-terminus cooperates with the C-terminus for kAE1 basolateral localization. Interestingly, Tyr 359 , in the N-terminal domain, and Tyr 904 in the C-terminus of AE1 are phosphorylated in red blood cells. A potential scheme is suggested where successive phosphorylation of these residues is necessary for correct localization and recycling of kAE1 to the basolateral membrane.
Introduction
The AE1 (anion-exchanger 1; red blood cell Band 3, SLC4A1) is a multispanning membrane protein that conducts chloride-bicarbonate exchange in the red blood cell and in the distal nephron of the kidney (reviewed in [1] ). The protein consists of an N-terminal cytoplasmic domain (amino acids 1-359), which associates with peripheral membrane proteins and forms a membraneanchorage site for the red blood cell cytoskeleton, and a C-terminal domain (amino acids 360-911), which carries out anion-exchange and consists of 12-14 TM (transmembrane) segments and includes a short (33-amino-acid) cytoplasmic C-terminal tail. The N-terminal cytoplasmic domain is known to bind ankyrin, protein 4.1, protein 4.2, glycolytic enzymes and haemoglobin [2] . The C-terminal tail harbours a binding site for carbonic anhydrase II [3, 4] . Together, AE1 and carbonic anhydrase II are suggested to form a 'metabolon', resulting in highly efficient chloride-bicarbonate exchange [5] .
The kidney isoform of AE1 (kAE1) is identical with AE1, but lacks the Nterminal 65 amino acids of AE1 [6] . This N-terminal truncation removes a central ␤-strand in the structural model of AE1, probably resulting in substantial changes in the N-terminal structure and binding properties of kAE1 [2, 7] .
Therefore the N-termini of kAE1 and AE1 are likely to interact with different intracellular proteins, but, aside from kanadaptin [8] (whose binding to kAE1 now looks doubtful [9] ), no candidate interactors with the N-terminus of kAE1 have been reported. kAE1 is located in the basolateral membrane of kidney ␣-intercalated cells [10] [11] [12] and is required for acid secretion into urine (see Figure 1) . The apical H ϩ -ATPase of the ␣-intercalated cell pumps protons derived from hydrated CO 2 into the tubular lumen, while kAE1 reclaims the remaining bicarbonate back into the blood in exchange for chloride.
dRTA (distal renal tubular acidosis) is characterized by defective acid secretion by the ␣-intercalated cells. AE1 gene mutations have been reported for both dominant and recessive forms of dRTA [13] [14] [15] [16] [17] [18] [19] . AE1 mutations that cause Band-3-linked hereditary spherocytosis or SAO (Southeast Asian ovalocytosis) in red blood cells, do not generally cause dRTA, unless present in homozygous form as in the Band-3-null individual [20] . In addition to mutations in AE1, mutations in the H ϩ -ATPase subunits have also been described in recessive dRTA [21] [22] [23] .
To date, all reported dominantly inherited forms of dRTA result from mutations in the AE1 gene, and reside exclusively in the AE1 membrane domain and C-terminal tail (see Figure 2) . The most prevalent, and thus most clinically significant, inherited forms of dRTA are associated with alterations of a conserved arginine at residue 589 (Arg 589 →His, Arg 589 →Ser and Arg 589 →Cys) located at the start of the cytoplasmic loop joining TM spans) 6 and 7 [13, 15, 19] . The other reported dominant mutations include Ser 613 →Phe in TM7 [13] , Ala 858 →Asp in the final TM [14] and two truncations of the Cterminus that result in an 11-amino-acid deletion of the C-terminus (Arg 901 →stop; Band 3 Walton) [19, 24] or a 23-amino-acid deletion [25] . Mutations that cause recessive dRTA have been described in Southeast Asia, and include Arg 602 →His within TM7 [26] , Gly 701 →Asp in the fourth cytoplasmic loop [14, 17, 18, 26] , Ser 773 →Pro in TM11 [26] and deletion of Val 850 in TM13 [14] . The recessive mutations are often found as compound heterozygotes with SAO [14, 17] , due to the high prevalence of the latter mutation in this region. When presented in conjunction with SAO, the recessive dRTA mutations have a more severe effect. This is partly due to the presence of functionally inactive SAO causing a pseudodominant phenotype, but also due to interactions that occur between the kAE1 SAO protein and the dRTA proteins exacerbating further the structural and functional characteristics of the dRTA protein [14, 27] .
The dominant dRTA mutant AE1 proteins all retain substantial aniontransport activity in mutant red blood cells and when the kAE1 proteins are expressed in Xenopus oocyte [13] [14] [15] [16] 24] . In addition, the observation that a single normal kAE1 allele can provide adequate acid secretion by the intercalated cells (as is the case in SAO [13, 14] ), suggests that dominant dRTA does not result from a simple reduction in anion-transport activity of the mutant kAE1. Alternative mechanisms proposed for the dominant disease include mistargeting of the mutant protein to the apical membrane and/or altered targeting of the normal protein by interaction with the mutant protein [13, 15] . Several recent studies have described the successful expression of both wild-type and dominant dRTA mutations in non-polarized [24, 28, 29] and polarized kidney cells [16, 30, 31] . This emerging body of work suggests that dominant dRTA mutations cause aberrant targeting of kAE1 in the intercalated cell, and also implicates specific regions of the kAE1 membrane domain for kAE1 trafficking in the kidney. This review will discuss the implications of these findings for our understanding of the dominant dRTA disease mechanism, and also the basolateral trafficking of kAE1 in intercalated cells.
kAE1 expression in mammalian cells
To date, most heterologous expression, particularly for topological studies of AE1, has been carried out using transiently transfected HEK-293 (human embryonic kidney) cells [32] [33] [34] [35] . Although HEK-293 cells successfully express both AE1 and kAE1 at the plasma membrane, a major disadvantage is that these cells are unable to polarize into distinct apical and basolateral membrane domains. In addition, post-translational modifications of AE1 and kAE1, such as complex N-glycosylation [29, 36] and palmitoylation [37] do not occur in HEK-293 cells (which appears to have no adverse effect on bicarbonate-chloride exchange conducted by AE1). AE1 and kAE1 have also been stably expressed at the cell surface in K562 cells [38, 39] , which facilitated the identifi- cation of the optimum confocal-imaging conditions for visualizing both proteins in mammalian cells [39] . Adair-Kirk et al. [40] were the first to investigate kAE1 trafficking in polarized MDCK (Madin-Darby canine kidney) I cells, finding that the major chicken-specific kidney AE1 isoform (AE1-4) was targeted to the basolateral membrane. AE1-4 basolateral sorting, Golgi recycling from the cell surface and the association with the actin cytoskeleton depended on tyrosine residues in the N-terminus [40] . However, in mammalian cells, this N-terminal sequence is present in erythrocyte AE1, but is absent in kAE1. Therefore there are likely to be species-specific differences in kAE1-targeting mechanisms between human and chicken kidney anion-exchangers.
Human kAE1 has now been expressed transiently in MDCKI [16, 31] and LLC-PK1 (porcine kidney) cells [30] , and stably in MDCKI cells [24, 30] . kAE1 was progressively converted from a core glycosylated form to a complex glycosylated form in both non-polarized and polarized MDCKI cells [30] . Immunofluorescence studies showed expression of kAE1 predominantly at the cell surface in non-polarized MDCKI cells (51Ϯ6% by biotinylation studies), with variable amounts of intracellular material that co-localized with markers of the secretory pathway [e.g. Golgi and TGN (trans-Golgi network)] [24, 30] . Importantly, kAE1 also localized to the basolateral membrane in MDCKI cells and LLC-PK1 cells [16, 30, 31] when these cells were allowed to polarize.
Unexpectedly, overexpression of wild-type kAE1 reduced the transepithelial electrical resistance and increased the permeability of the paracellular barrier of the polarized MDCKI monolayers to a normally impermeant biotinylation reagent [30] . However, the localization of the tight junction marker ZO-1 (zona occludens 1 protein) was unaffected in these cells [30] . The increased permeability of the paracellular barrier occurred with wild-type kAE1 and not the kAE1 (Arg 901 →stop) mutant, implicating the involvement of the C-terminal residues of kAE1. It was suggested that kAE1 overexpression may interfere with the actin/spectrin cytoskeleton, therefore affecting the organization of the paracellular permeability barrier provided by epithelial tight junctions [30] . Another possibility is that kAE1 overexpression affects MDCKI epithelial cell-cell adherence and therefore paracellular permeability. This is because the C-terminal tail of kAE1 contains a tyrosine motif [YDEV (Tyr-Asp-Glu-Val), see below], which is similar to a tyrosine motif [YSEV (Tyr-Ser-Glu-Val)] contained in the cytoplasmic domain of CEACAM1-L (long isoform of carcinoembryonic antigen-related cell-adhesion molecule 1) that perturbed desmosomes and disorganized cytokeratin filaments [41] .
Mistrafficking of dRTA mutants affecting the putative TM6-7 region of kAE1
Five of the eight dominant dRTA variants reported are located in the region of kAE1 encompassing TMs 6 and 7 (see Figure 2) , with three of these mutations affecting the conserved Arg 589 . The kAE1 (Arg 589 →His), kAE1 (Arg 589 →Ser) and kAE1 (Arg 589 →Cys) proteins were transiently expressed in non-polarized HEK-293 cells, and all were retained within the ER (endoplasDefective kidney anion-exchanger 1 trafficking in dominant distal renal tubular acidosis 51 mic reticulum) [29] . Importantly, kAE1 (Arg 589 →His) formed heterooligomers with wild-type kAE1 and had a dominant-negative effect on the ability of wild-type protein to reach the cell surface. The mutant did not affect wild-type erythrocyte AE1 trafficking, suggesting that the additional 65 amino acids present in erythrocyte AE1 helped the protein evade this dominant-negative effect [29] . Both kAE1 (Arg 589 →His) and kAE1 (Ser 613 →Phe) dRTA mutations were also retained internally when stably expressed in non-polarized and polarized MDCKI cells [30] . Incubation of these cells at 27ЊC, which corrects CFTR(⌬F508) (cystic fibrosis transmembrane conductance regulator with a deletion of Phe 508 ) mistrafficking in transfected cells [42] , did not alter the mistrafficking of Arg 589 →His or Ser 613 →Phe [30] . It is unlikely that the Arg 589 →His and Ser 613 →Phe dRTA mutations cause gross misfolding of the mutant proteins, since they have significant transport activity in both Xenopus oocytes and red blood cells [13, 15, 16] . In addition, TM6-7 appear not to be essential for AE1 chloride transport [43] . It is possible that localized misfolding in the TM 6 and 7 region increases the aggregation of the mutant proteins or alters their interactions with ER chaperones. This would affect their exit from the ER, and may then lead to their degradation by the ERAD (ER-associated degradation) system.
Recently, a dominant dRTA mutation (Gly 609 →Arg) [16] and a recessive dRTA mutation (Arg 602 →His) [26] have been reported. Despite the close proximity of both Arg 602 →His and Gly 609 →Arg to the Ser 613 →Phe dRTA mutation, Arg 602 →His is reported as being recessive [26] and the Gly 609 →Arg mutation had both apical and basolateral distribution (termed non-polarized when transiently expressed in MDCKI cells) [16] . These data indicate that, although dRTA mutations are clustered between the TM6-7 region of kAE1, they can still affect kAE1 function and activity in subtly different ways.
Effects of dominant dRTA mutations in the final TM and cytoplasmic C-terminus of kAE1
Three dominant dRTA mutations occur within the final TM and the short cytosolic C-terminal tail of kAE1 (see Figure 2 ). These are Ala 858 →Asp within the final TM [14] and two truncations of the cytoplasmic C-terminus, one of 11 amino acids (Band 3 Walton, Arg 901 →stop) [19, 24] and the other of 23 amino acids [25] . Both the Ala 858 →Asp and the Arg 901 →stop mutations had significant chloride-chloride exchange activity in red blood cells and Xenopus oocytes [14, 24] , but the effects of the 23-amino-acid truncation mutant have not been investigated.
Topological studies on AE1, position residue 858 within the outer leaflet of the lipid bilayer (near the extracellular face of the plasma membrane) in the final TM [32, 35, 44] . This residue is suggested to form part of a hydrophobic pore, lining the anion-translocation channel of AE1 [44] . The effect of the Ala 858 →Asp mutation on kAE1 trafficking in kidney cells has not been studied, but the Ala 858 →Cys mutant used in the cysteine-scanning mutagenesis experiments had significant transport in HEK-293 cells [35] . In a similar way to the recessive dRTA mutants, compound heterozygotes with SAO and Ala 858 →Asp had a more severe form of dRTA, and also anaemia [14] . This suggests that hetero-oligomerization of Ala 858 →Asp with the mutant SAO protein, can exacerbate further the structural/functional effects of the Ala 858 →Asp mutation in the patients' ␣-intercalated cells and red blood cells [14, 27] .
The Arg 901 →stop form of kAE1 is the most studied dRTA mutation, having been expressed in MDCKI [24, 30, 31] , LLC-PK1 [30] and HEK-293 [28, 45] cells. In non-polarized cells, the majority of kAE1 (Arg 901 →stop) is retained internally, co-localizing with calnexin in both MDCKI and HEK-293 cells [24, 28, 30] . However, cell-specific differences in the trafficking of the Arg 901 →stop mutant appear to exist, since the protein is able to exit the ER and mistarget to late endosomes/lysosomes in MDCKI cells, but this does not occur in HEK-293 cells [28, 30] . In addition, kAE1 (Arg 901 →stop) is complex N-glycosylated in MDCKI cells, but the complex N-glycan is larger than that on the wild-type [30] . This was suggested to indicate that the protein traffics differently from normal kAE1, with a longer transit time through the medial Golgi, or increased recycling of the mutant protein. As found for the Arg 589 →His mutation, kAE1 (Arg 901 →stop) could form hetero-oligomers with wild-type kAE1, and have a dominant-negative effect on the ability of wildtype protein to reach the cell surface in HEK-293 cells [28] . The Arg 901 →stop mutation also affects AE1 trafficking in HEK-293 cells, but not in red blood cells or when it was expressed in Xenopus oocytes [24] . This highlights differences in AE1 trafficking between the kidney cells, red blood cells and oocytes, and suggests that the C-terminus is not as important for trafficking in red blood cells or oocytes, as it is in the kidney [24] . In addition, the presence of AE1-interacting proteins such as glycophorin A [46] in red blood cells could also help alleviate the trafficking defect of this mutation.
In polarized MDCKI cells stably expressing kAE1 (Arg 901 →stop), the mutant protein was mistargeted to the apical plasma membrane, as judged by immunofluorescence and domain-selective biotinylation [30] . However, transient expression of kAE1 results in a non-polarized distribution in both polarized MDCKI [31] and polarized LLC-PK1 [30] cells. A potential explanation for the purely apical localization observed in stably transfected cells and the non-polarized distribution in transiently transfected cells could be that transient overexpression of kAE1 saturates the cellular sorting machinery allowing some kAE1 (Arg 901 →stop) to reside at the basolateral membrane. Alternatively, in polarized cells, kAE1 (Arg 901 →stop) may be delivered initially to the basolateral plasma membrane, then rapidly internalized prior to delivery to the apical plasma membrane. In cells transiently overexpressing kAE1 (Arg 901 →stop), there would be more kAE1 (Arg 901 →stop) detected at the basolateral membrane, whereas, in stable cells, the amount is below the level of detection.
The different localizations of the normal kAE1 and the kAE1 (Arg 901 →stop) in non-polarized and polarized MDCKI cells, suggest that the C-terminal 11 residues of kAE1 (-RDEYDEVAMPV) contains both a plasmamembrane-targeting determinant (in non-polarized cells) and a basolateral-targeting or -retention determinant (in polarized cells). The removal of the C-terminus determinant would then allow previously cryptic/suppressed signals to predominate in the non-polarized and polarized cells.
These findings would also predict that the 23-amino-acid C-terminal truncation may have a similar effect to Arg 901 →stop, since the same C-terminal sorting determinant would be absent in this mutation. The 23-amino-acid truncation may also make kAE1 more unstable, since C-terminal truncations of AE1 greater than 20 amino acids are unstable in Xenopus oocytes [47] and HEK-293 cells [45] . The 23-amino-acid truncation mutation also affects the binding site for carbonic anhydrase II [48] , so is also likely to alter the interaction of kAE1 with carbonic anhydrase II.
Mechanisms leading to dominant dRTA associated with kAE1 mutations
It is clear that kAE1 mutations associated with dominant dRTA affect the targeting of kAE1 in kidney cells. However, these dominant mutations result in disease even though the patients carry a normal AE1 allele as well as the mutant allele. Research to date suggests that dominant dRTA can arise by at least two mechanisms that involve either the intracellular retention of wild-type protein or mistargeting of the mutant protein to the apical plasma membrane (see Figure 3 ). Similar mechanisms have recently been reported for other dominant diseases, such as familial hypercholesterolaemia and autosomal dominant diabetes insipidus [49] [50] [51] .
Both the Arg 589 →His and Ser 613 →Phe mutations probably result in the intracellular retention of the wild-type kAE1 due to its association with the mutant protein in the form of higher-order hetero-oligomers/aggregates (Figure 3) . A similar hetero-oligomerization was observed for the SAO protein with wild-type AE1, where, strikingly, all the wild-type kAE1 forms heterooligomers with the mutant SAO protein [27] . The intracellular retention of wild-type kAE1 may then lead to the destruction of normal kAE1 protein by the ERAD pathway or another degradative pathway. In support of this hypothesis, a kidney resection from an Arg 589 →His patient appeared to have no detectable AE1 immunoreactivity [52] .
Both kAE1 (Arg 901 →stop) and kAE1 (Gly 609 →Arg) mutations appear to mistarget the protein to the apical plasma membrane [16, 30, 31] (Figure 3) . The presence of the mistargeted bicarbonate-chloride exchanger at the apical membrane would allow bicarbonate to move into the tubular lumen together with protons secreted by the H ϩ -ATPase, thus negating net acid secretion by the cells. In addition, the kAE1 (Arg 901 →stop) mutant [and potentially kAE1 (Gly 609 →Arg)] could hetero-oligomerize with wild-type kAE1 [28] , which may then also misroute the normal protein to the apical membrane via the formation of hetero-oligomers. However, these hetero-oligomers would still contain wildtype copies of kAE1, which, hypothetically, should still contain signals to direct the hetero-oligomers to the basolateral membrane. Failure of such heterooligomers to be delivered to the basolateral plasma membrane would indicate that, in this case, the apical targeting information in kAE1 (Arg 901 →stop) protein overrides the basolateral targeting information on the wild-type protein. The reverse situation is illustrated by a dominant AQP-2 (aquaporin-2) mutant that has a basolateral-targeting motif in the C-terminus due to a frameshift mutation, and mistargets the normally apical wild-type AQP-2 to the basolateral membrane [53] . Further experiments utilizing polarized cells co-expressing wild-type and mutant kAE1 are needed to address this hypothesis. Initial attempts to investigate co-expression of wild-type and dRTA mutants in polarized cells using transient transfection were unsuccessful [30] . Stable MDCKI cells have now been developed that co-express both wild-type kAE1 and dRTA mutant kAE1 (A.M. Toye, unpublished work). It is hoped that polarization of these stable cells will help to define more conclusively the molecular basis of the disease associated with dRTA kAE1 mutations.
Basolateral-targeting signals in the N-and C-termini of kAE1
Results from investigations of the kAE1 (Arg 901 →stop) dRTA mutant [30, 31] , and also the removal of the N-terminus of kAE1 [30] , demonstrated that kAE1 has two basolateral determinants, one in the N-terminus and one in the Cterminus. The deletion of either the N-or the C-terminus results in the apical localization of the protein, suggesting that the presence of both determinants is essential for correct basolateral localization of kAE1. In non-polarized MDCKI cells, only the C-terminal determinant was required for plasma-membrane-targeting [30] ; this illustrates the greater complexity of the polarized cell system.
The nature of the N-terminal basolateral determinant of human kAE1 has not been defined. Chicken kidney AE1-4 has two basolateral localization determinants in the N-terminus [40] , but these are absent in human kAE1. The human kAE1 N-terminal domain may also contain a basolateral retention/sorting signal, or it may have a role in the polarized trafficking pathway before/after the C-terminus becomes involved. Alternatively, both the Nand the C-termini might interact simultaneously with as yet unidentified targeting machinery. The human kAE1 N-terminal domain has several conserved potential targeting motifs that are not present in chicken kAE1, and these are being evaluated at present.
Analysis of the sequence of the C-terminal tail of human AE1 reveals several motifs that appear to be conserved among the three AE1 family members and AE1 orthologues (Figure 4) . The sequence -Y 904 DEV-(of human AE1) within the C-terminus conforms to the consensus motif -YXX⌽-(where ⌽ is a bulky hydrophobic residue), which binds to medium-chain subunits of adaptor complexes involved in various clathrin-dependent and -independent trafficking events [54] [55] [56] [57] [58] . Directly adjacent to the tyrosine-based sorting signal in kAE1 is a type II PDZ binding motif (Ala-Met-Pro-Val), which can bind PICK-1 (protein interacting with protein kinase C 1) [59] . PDZ-binding domain proteins are widely expressed, are often involved in targeting and regulation of membrane proteins [60] , and can retain apical or basolateral membrane proteins in their respective domains [61, 62] . The C-terminus also contains repeats of di-acidic amino acids (Asp-Glu or Glu-Glu), some of which may also be important in kAE1 trafficking.
The -Y 904 DEV-, but not the C-terminal PDZ-binding motif, is critical for kAE1 basolateral localization [30] . Substitution of alanine or phenylalanine for Tyr 904 alters kAE1 trafficking [30, 31] . This tyrosine motif may interact directly with adaptor proteins that are necessary for basolateral targeting of kAE1. However, the adaptor complex AP-1B (activator protein 1B), which mediates basolateral sorting of some membrane proteins in epithelial cells [63] , is not necessary for kAE1 trafficking to the basolateral membrane [30, 31] . Therefore another adaptor complex, such as AP-4 [64] or other unidentified components, may direct kAE1 to the basolateral membrane.
kAE1 can tolerate the substitution of an alanine for valine at the Tyrϩ3 position in the C-terminal YXX⌽ motif. Alanine is present at the Tyrϩ3 position in the basolateral tyrosine sorting motif of the Na ϩ -taurocholate co-transporter, which may not require a clathrin-adaptor complex for basolateral targeting [65] . Therefore either the basolateral-targeting machinery that interacts with kAE1 can tolerate the Val 907 →Ala substitution or kAE1 (Val 907 →Ala) can be targeted to the basolateral membrane by an alternative mechanism to that used by the wild-type protein.
Although not essential for kidney basolateral targeting, removal of the PDZ-interacting domain increased intracellular kAE1 levels observed in polarized MDCKI cells [30] . Therefore the PDZ-binding domain may still have some role to play in the efficient trafficking to, or retention at, the basolateral membrane. Of interest is the finding that the PDZ-binding domain of the NMDA (N-methyl-D-aspartate) receptor has a role in the direct targeting of this neuronal protein to the synapse [66] . Sans et al. [66] suggested two potential pathways for trafficking to the plasma membrane, a direct pathway that utilizes the exocyst complex (possibly used by newly synthesized proteins) and an endosomal route. Hence, if the PDZ-binding domain of kAE1 was involved in a direct route of targeting to the plasma membrane, its removal would still leave the endosomal pathway to predominate (see Figure 5 ). Therefore the Y 904 DEV motif may function as a basolateral/endosomal recycling motif, which enables the return of internalized kAE1 protein back to the cell surface.
A potential role for tyrosine phosphorylation in kAE1 trafficking
Tyrosine phosphorylation can influence the localization of proteins by regulating their interactions with cellular targeting and/or internalization machinery [41, [67] [68] [69] [70] . Both Tyr 359 in the N-terminal domain and Tyr 904 in the C-terminus of AE1 are phosphorylated in red blood cells [71] , and are present in kAE1. A potential role for phosphorylation in the basolateral localization of kAE1 was recently suggested by the observation that the substitution of phenylalanine for Tyr 904 alters kAE1 targeting [30] . Further work is necessary to investigate the potential role of this Tyr 904 phosphorylation in the polarized targeting of kAE1. However, it is tempting to draw parallels with other proteins where phosphorylation is known to regulate the levels of the protein at the cell surface. In particular, the Y 904 DEV motif is very similar to Y 515 SEV of CEACAM1-L, which, when phosphorylated, causes internalization of CEA-CAM1-L from the basolateral plasma membrane [41] . In addition, substitution of alanine or phenylalanine for Tyr 515 in CEACAM1-L restricts this protein to the apical membrane. Furthermore, substitution of alanine for valine at the Tyrϩ3 position did not affect the basolateral localization of CEACAM1-L (as with kAE1), but did reduce the level of phosphorylation of the tyrosine residue (and therefore decreased internalization of this protein). Currently, it is unknown what regulates the delivery of kAE1 to the basolateral plasma membrane of ␣-intercalated cells or its internalization from that membrane. However, if it is assumed that phosphorylation of the Tyr 904 residue in kAE1 may occur (analogous to the phosphorylated Tyr 515 in CEACAM1-L), then it is possible to suggest a scheme that explains why both the N-and C-termini are required for basolateral targeting (see Figure 6 ). Thus, if phosphorylation of Tyr 904 enhances the internalization of kAE1 (as phosphorylation of Tyr 515 does in the case of CEACAM1-L), then the Tyr 904 residue must also be dephosphorylated in order for the Y 904 DEV basolateral-targeting motif to be recognized and allow recycling of kAE1 back to the basolateral membrane. This is where I would speculate that the N-terminal Tyr 359 residue (of AE1) may be necessary, as, in the red blood cell, phosphorylation of Tyr 359 recruits the phosphatase SHP-2 (Src-homology-2-domain-containing tyrosine phosphatase 2), which in turn dephosphorylates the Tyr 904 residue [72] (see Figure 6 ). If a similar process occurs in the ␣-intercalated cell, this would enable the recycling of kAE1 back to the basolateral plasma membrane. This hypothesis, if correct, also provides a mechanism for the intercalated cells to regulate the levels of kAE1 at the basolateral plasma membrane in response to cues such as metabolic acidosis.
Conclusion
Until relatively recently, very little was known about the properties of kAE1 targeting and regulation in the ␣-intercalated cell. The observation that specific AE1 gene mutations cause dominant dRTA in the kidney, but have little effect on the red blood cell AE1 or when kAE1 mutants were expressed in Xenopus oocytes, strongly suggested that these mutations affected regions of kAE1 protein important for its correct function in the kidney [13, 15, 19, 24] . The recent development of transfected polarizable cell models of kAE1 has confirmed this hypothesis, suggesting that dominant dRTA mutations can cause the intracellular retention of the mutant protein, or result in the protein being mistargeted to the apical plasma membrane [16, 30, 31] . This aberrant targeting of kAE1 [16, 24, [28] [29] [30] [31] , alongside the retained ability of these mutant proteins to form hetero-oligomers with the wild-type kAE1 protein [28, 29] , explains the molecular mechanism behind dominant dRTA.
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It is now clear that specific regions within kAE1 (the cytoplasmic N-terminus, residues between TM6 and TM7 and the cytoplasmic C-terminal tail) [30, 31] are critical for correct localization of this basolateral protein. Therefore, by investigating the effects of dRTA mutations and also the regions of the kAE1 that they influence, we have opened up new avenues of research into kAE1 trafficking. It is hoped that the continuation of these studies will provide valuable insights into how mutations in oligomeric multispanning membrane proteins can cause human disease, and also provide valuable information regarding protein trafficking in polarized cells. would then require the action of a phosphatase to dephosphorylate this residue, to then re-expose the -YDEV-basolateral sorting motif to enable recycling of kAE1 back to the basolateral membrane. This dephosphorylation is proposed to be carried out in the endosomes by the phosphatase SHP-2 (or an analogous phosphatase) that is recruited to kAE1 by the phosphorylation of residue Tyr 359 (PhosY359). TJ, tight junction.
